logo ecco
Portal

ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

Poster presentations: Clinical: Therapy and Observation 2020

P707 Anti-TNFα therapy has no effect on bone mineral density in younger patients with inflammatory bowel disease: A single-centre observational study

R. Filip1,2, S. Jarmakiewicz - Czaja3, D. Piątek4, J. Sztembis5, A. Pękala1, W. Guz6

1Department of Gastroenterology with IBD Unit, Clinical Hospital No.2- Rzeszow, Rzeszow, Poland, 2Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland, 3Institute of Health Sciences, Medical College of Rzeszow University, Rzeszow, Poland, 4Department of Conservative Dentistry with Endodontics, Medical University of Lublin, Lublin, Poland, 5Department of Internal Medicine- Endocrinology- Nephrology, Clinical Hospital No.2 Rzeszow, Rzeszow, Poland, 6Medical College of Rzeszow University

Background

Active inflammation negatively affects bone mineral density. Biological treatment, among others silences the excessive reaction of the immune system, which can also reduce the risk of osteoporosis. The aim of the study is to determine whether bone mineral density is higher in patients with biological therapy.

Methods

In total, 112 patients over 18 years of age with CD (Crohn’s Disease) or UC (Ulcerative colitis) were included in the study. The mean value age was 35 years. Patients who had received anti-TNFα therapy (biosimilar infliximab CT-P13 or adalimumab), and who underwent densitometric evaluation after two year treatment, were selected. Those who had never received anti-TNFα therapy were selected as controls. Information regarding age, sex, weight, duration of CD, use of glucocorticoids and bisphosphonates, and signs of disease activity at the time of densitometric measurement were collected. Bone mineral density was measured by dual-energy X-ray absorptiometry (DEXA) within femoral neck and lumbar spine. Results are reported as g/cm2 and presented either as Z-score or as a T-score.

Results

The study group has characterised a mean value BMI (Body Mass Index)—24. The group of patients with anti-TNFαα therapy showed an average T-score left femur −0.7744 (CD) and −0.4382 (UC), but without anti-TNFα therapy −0.6636 (CD) and −0.2208 (UC). The entire study group showed a mean value t-score left femur of −0.54286. There were no significant statistical differences between the examined groups and the effect of anti-TNFα therapy on BMI, T-score left femur, T-score L2–L4

Studied factorAverageMedianStandard deviationLower quartileUpper quartileStatistical analysis
Crohn’s disease (CD)
Anti-TNFα therapy
BMI23.137221.70003.6728120.100026.6000p > 0.05
L2–L4 T-score−0.4953−0.60001.36468−1.50000.7000
Left femur T-score−0.7744−0.80001.03420−1.8000−0.1000
No anti-TNFα therapy
BMI23.654524.00003.5654920.500026.6000p > 0.05
L2–L4 T -score−0.3273−0.60001.33423−1.10000.8000
Left femur T-score−0.6636−0.80000.79909−1.1000−0.3000
Colitis ulcerosa (UC)
Anti-TNFα therapy
BMI26.020623.950011.2713820.500028.2000p > 0.05
L2-L4 T -score−0.1529−0.20001.30853−1.00000.7000
Left femur T - score−0.4382−0.40001.06002−1.20000.0000
No anti-TNFα therapy
BMI23.883322.75004.8391220.500027.9000p > 0.05
L2-L4 T-score0.08330.00001.27541−0.65001.0500
Left femur T-score−0.2208−0.25000.83613−0.80000.2000

Conclusion

The results of the preliminary study assessing the effect of anti-TNFα therapy on bone mineral density among the two treatment groups (CD and UC) do not indicate significant differences after the introduction of such therapy